TiGenix

About:

TiGenix is a biomedical company focused on research and development of innovative local treatments for damaged and osteoarthritic joints.

Website: http://www.tigenix.com

Twitter/X: tigenix

Top Investors: Capricorn Partners, Kreos Capital, Ysios Capital, Auriga Partners, Crede CapitalGroup

Description:

TiGenix NV (TiGenix) and its subsidiaries TiGenix Inc. and TC CEF LLC. is a Belgium-based biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. The Company is exploiting the power of regenerative medicine for the development of durable treatments, validated through controlled clinical studies, for these indications. TiGenix is located in Leuven and was founded as a spin-off of the Catholic University of Leuven and the University of Ghent. TiGenix is developing a portfolio of products that addresses specific musculoskeletal problems. The lead indication among these is cartilage damage, which is a debilitating affliction severely affecting the mobility and functioning of patients. During the fiscal year ended December 31, 2009, the Company acquired Orthomimetics Ltd.